Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Young-Rak Cho

Showing results (101-110 of 112) with videos related to

Pageof 12
Sort By:
The American Journal of Cardiology|June 4, 2015
Comparison of Coronary Computed Tomographic Angiographic Findings in Asymptomatic Subjects With Versus Without Diabetes MellitusGyung-Min Park, Jae-Hwan Lee, Seung-Whan Lee, et al.
Heart (British Cardiac Society)|September 10, 2025
Off-label underdosing of edoxaban antithrombotic therapy for patients with atrial fibrillation and stable coronary artery disease: findings from the EPIC-CAD trialMin Soo Cho, Do-Yoon Kang, Jung-Bok Lee, et al.
International Journal of Cardiology|May 26, 2017
Prediabetes is not a risk factor for subclinical coronary atherosclerosisGyung-Min Park, Young-Rak Cho, Seung-Whan Lee, et al.
JACC. Asia|February 28, 2026
Sex-Based Differences in Clinical Outcomes With Edoxaban Therapy: A Prespecified Analysis of the EPIC-CAD TrialGi-Hwan Kim, MinSoo Cho, Seonok Kim, et al.
The New England Journal of Medicine|September 3, 2024
Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery DiseaseMin Soo Cho, Do-Yoon Kang, Jung-Min Ahn, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|April 20, 2026
Impact of renal function on edoxaban antithrombotic therapy in patients with atrial fibrillation and stable coronary artery disease: a prespecified analysis of the EPIC-CAD trialJoong Min Lee, Min Soo Cho, Do-Yoon Kang, et al.
Journal of the American Heart Association|March 18, 2026
Impact of Atrial Fibrillation Pattern on Edoxaban Antithrombotic Therapy in Patients With Atrial Fibrillation and Stable Coronary Artery Disease: A Secondary Analysis of the EPIC-CAD Randomized Clinical TrialJae-Sung Yu, Min-Soo Cho, Do-Yoon Kang, et al.
Circulation. Cardiovascular Interventions|October 11, 2012
Comparison of resolute zotarolimus-eluting stents and sirolimus-eluting stents in patients with de novo long coronary artery lesions: a randomized LONG-DES IV trialJung-Min Ahn, Duk-Woo Park, Young-Hak Kim, et al.
The American Journal of Cardiology|September 26, 2013
Comparison of Zotarolimus-Eluting stent versus Sirolimus-Eluting stent for de novo coronary artery disease in patients with diabetes mellitus from the ESSENCE-DIABETES II trialGyung-Min Park, Seung-Whan Lee, Seong-Wook Park, et al.
European Heart Journal|August 31, 2025
Temporal modulation of antiplatelet therapy in high-risk patients undergoing complex percutaneous coronary intervention: the TAILORED-CHIP randomized clinical trialDo-Yoon Kang, Seong-Bong Wee, Jung-Min Ahn, et al.
Pageof 12

Showing results (101-110 of 112) with videos related to

Sort By:
Pageof 12
The American Journal of Cardiology|June 4, 2015
Comparison of Coronary Computed Tomographic Angiographic Findings in Asymptomatic Subjects With Versus Without Diabetes MellitusGyung-Min Park, Jae-Hwan Lee, Seung-Whan Lee, et al.
Heart (British Cardiac Society)|September 10, 2025
Off-label underdosing of edoxaban antithrombotic therapy for patients with atrial fibrillation and stable coronary artery disease: findings from the EPIC-CAD trialMin Soo Cho, Do-Yoon Kang, Jung-Bok Lee, et al.
International Journal of Cardiology|May 26, 2017
Prediabetes is not a risk factor for subclinical coronary atherosclerosisGyung-Min Park, Young-Rak Cho, Seung-Whan Lee, et al.
JACC. Asia|February 28, 2026
Sex-Based Differences in Clinical Outcomes With Edoxaban Therapy: A Prespecified Analysis of the EPIC-CAD TrialGi-Hwan Kim, MinSoo Cho, Seonok Kim, et al.
The New England Journal of Medicine|September 3, 2024
Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery DiseaseMin Soo Cho, Do-Yoon Kang, Jung-Min Ahn, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|April 20, 2026
Impact of renal function on edoxaban antithrombotic therapy in patients with atrial fibrillation and stable coronary artery disease: a prespecified analysis of the EPIC-CAD trialJoong Min Lee, Min Soo Cho, Do-Yoon Kang, et al.
Journal of the American Heart Association|March 18, 2026
Impact of Atrial Fibrillation Pattern on Edoxaban Antithrombotic Therapy in Patients With Atrial Fibrillation and Stable Coronary Artery Disease: A Secondary Analysis of the EPIC-CAD Randomized Clinical TrialJae-Sung Yu, Min-Soo Cho, Do-Yoon Kang, et al.
Circulation. Cardiovascular Interventions|October 11, 2012
Comparison of resolute zotarolimus-eluting stents and sirolimus-eluting stents in patients with de novo long coronary artery lesions: a randomized LONG-DES IV trialJung-Min Ahn, Duk-Woo Park, Young-Hak Kim, et al.
The American Journal of Cardiology|September 26, 2013
Comparison of Zotarolimus-Eluting stent versus Sirolimus-Eluting stent for de novo coronary artery disease in patients with diabetes mellitus from the ESSENCE-DIABETES II trialGyung-Min Park, Seung-Whan Lee, Seong-Wook Park, et al.
European Heart Journal|August 31, 2025
Temporal modulation of antiplatelet therapy in high-risk patients undergoing complex percutaneous coronary intervention: the TAILORED-CHIP randomized clinical trialDo-Yoon Kang, Seong-Bong Wee, Jung-Min Ahn, et al.
Pageof 12